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ABSTRACT: Targeted resequencing gene panels are used
in the diagnostic setting to identify gene defects in epilepsy.
We performed targeted resequencing using a 30-genes
panel and a 95-genes panel in 349 patients with drug-
resistant epilepsies beginning in the first years of life. We
identified 71 pathogenic variants, 42 of which novel, in 30
genes, corresponding to 20.3% of the probands. In 66% of
mutation positive patients, epilepsy onset occurred before
the age of 6 months. The 95-genes panel allowed a genetic
diagnosis in 22 (6.3%) patients that would have other-
wise been missed using the 30-gene panel. About 50%
of mutations were identified in genes coding for sodium
and potassium channel components. SCN2A was the most
frequently mutated gene followed by SCN1A, KCNQ2,
STXBP1, SCN8A, CDKL5, and MECP2. Twenty-nine
mutations were identified in 23 additional genes, most of
them recently associated with epilepsy. Our data show
that panels targeting about 100 genes represent the best
cost-effective diagnostic option in pediatric drug-resistant
epilepsies. They enable molecular diagnosis of atypical
phenotypes, allowing to broaden phenotype–genotype cor-
relations. Molecular diagnosis might influence patients’
management and translate into better and specific treat-
ment recommendations in some conditions.
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Introduction
Many epilepsies and epilepsy syndromes have genetic causes
[Gourfinkel-An et al., 2004;Guerrini et al., 2006;Helbig et al., 2008].
Recent whole exome and genome sequencing studies focussing on
monogenic severe epilepsies and epileptic encephalopathies (EEs)
have indeed identified mutations in many genes [Epi4k Consor-
tium, 2013; Myers and Mefford, 2015; Helbig et al., 2016]. The
hypothesis of one gene-one disease has proven to be incorrect for
most syndromes, thus clinicians standstill with phenotypes that
might overlap but are associated with mutations in different genes
or might confront with a spectrum of phenotypes being caused
by mutations in the same gene [Carvill et al., 2013; Epi4k Con-
sortium, 2013]. Loose genotype–phenotype correlations place the
clinician in the difficult position of not knowing the most suit-
able candidate gene that might underlie the epilepsy afflicting the
young patient. Therefore, targeted resequencing of selected genes
(gene panels) appears to be the best cost-effective diagnostic op-
tion. Recent studies have indeed shown that gene panels have the
power of reaching a diagnosis in about 20% of probands with
severe epilepsies and developmental delay [Trump et al., 2016]
and such proportion might increase up to nearly 50% when the
number of genes included in the panel is very high and pa-
tients analyzed have a spectrum of hypothetically genetic epilepsies
[Lemke et al., 2012].
This study was conceived to elaborate on clinical and genetic
data of 349 patients with pediatric drug-resistant epilepsies an-
alyzed using targeted resequencing (next-generation sequencing;
NGS) with an initial panel of 30 genes and a second larger panel
of 95 genes, or both for a subset of patients. The panels include
major epilepsy genes and also genes that are not frequently anal-
ysed by standard methods. We identified 71 pathogenic variants
corresponding to 20.3% of the probands. Most mutations occurred
in probands with epilepsy onset before the age of 6 months and
laid in known epilepsy genes. SCN2A was the most frequently mu-
tated gene in 2.6% of the cohort followed by SCN1A, KCNQ2,
STXBP1, SCN8A, CDKL5, and MECP2. The larger panel identi-
fied additional mutations in rare genes and patients here described
contribute to delineate the associated, yet uncertain phenotypes.
Thus, this study contributes to confirm the utility of NGS gene
panels in a clinical diagnostic setting and the usefulness of using
panels comprehensive of both well-known and rarely associated
epilepsy genes, the later enabling molecular diagnosis of atypical
phenotypes.
C© 2016 WILEY PERIODICALS, INC.
Materials and Methods
We assembled a cohort of 349 consecutive patients, with no ob-
vious developmental or acquired brain abnormalities on 1.5T to
3T MRI or dysmorphic features, analyzed with NGS panels in
our Neurogenetics Laboratory from 2013 to 2015. Patients were
referred from the Pediatric Neurology Unit of the Anna Meyer
Children’s Hospital, as well as from other national and Euro-
pean epilepsy/neurology centers, and exhibited a wide spectrum
of pediatric drug-resistant epilepsies. We defined epilepsy as “drug-
resistant” when adequate trials of two tolerated, appropriately cho-
sen, and used antiepileptic drugs schedules (whether as monother-
apies or in combination) failed to achieve sustained seizure free-
dom [Kwan et al., 2010; Tellez-Zenteno et al., 2014]. We classified
seizure types and epilepsy/syndromes according to the ILAE guide-
lines [Commission on Classification and Terminology, 1989; Berg
et al., 2010]. Based upon age of seizures onset, we defined patients as
having: (a) neonatal onset epilepsy when seizures occurred within
the 1st month; (b) infantile epilepsy when presenting from the 1st
to the 12thmonth; (c) childhood epilepsy when presenting after the
1st year of life [Berg et al., 2010]. Within the infantile epilepsies,
patients with onset before 6 months of age are commonly referred
to as having an early infantile epilepsy.
NGSwasperformed in 207patientswith severe epilepsies (Cohort
A), predominantly either neonatal or infantile EEs, using a panel
of 30 known epilepsy genes. NGS was performed in a cohort of
142 probands (Cohort B) with a broader spectrum of drug-resistant
epilepsies using a larger panel targeting 95 genes associated with
epilepsy. The genes targeted by these panels are listed in Supp. Table
S1 and Supp. Table 2S. 34 out of the 207 patients of the Cohort
A, who resulted mutation negative to the 30-genes panel, were also
analyzed with the 95-genes panel.
We obtained approval for this study from the Institutional Re-
view Board of the Meyer Children’s Hospital. We obtained clinical
information and blood/DNA samples after informed consent.
DNA was extracted from peripheral blood leukocytes using a
QiaSymphonySP robot (Qiagen,Hilden,Germany) according to the
manufacturer’s protocol. High-quality DNA was quantified using a
Quantifluor Fluorometer (Promega, Madison, WI).
A subset of patients, prior to NGS, underwent Sanger sequencing
for one or more genes (Supp. Table S3). Array-CGHwas performed
in 109 patients (109/349: 31%).
30-Genes Panel Target Resequencing Analysis
The panel was designed using a custom target in solution enrich-
ment NimbleGen SeqCap EZ Choice Library (Roche Inc., Madison,
WI) to target the complete genomic sequence of selected genes, as
well as the flanking regions at the 5′ and 3′ ends of each gene, ac-
counting for a total of 109,528 bp. gDNA (500 ng) was nebulized
and the libraries prepared using a GS FLX Titanium Rapid Library
Preparation Kit (Roche Inc.). The libraries were multiplexed using
different MID identifiers in order to analyze up to 12 samples in
a single sequencing run, and the pool was hybridized to SeqCap
EZ Choice Library designed to capture the genes included in the
panel. Sequencing was performed according to the Roche FLX Ti-
tanium protocols and kits. Briefly, captured sample libraries were
subjected to emulsion-based clonal amplification. DNA-carrying
beads were enriched and used as template for sequencing by syn-
thesis using the Titanium chemistry (XLR70 GS FLX Titanium se-
quencing kit; Roche Inc.). GS FLX sequence reads were aligned to
the NCBI37/hg19 reference genome using the GS ReferenceMapper
v2.9 toolkit. Variants were called using the same toolkit. Exploiting
the long reads generated by the GS FLX sequencer, we used the GS
Reference Mapper to unravel potential structural rearrangements
in the 30-genes panel. As we identified only two rearrangements
involving the STXBP1 and MECP2 genes, we subsequently con-
firmed them byMultiplex Ligation-dependent Probe Amplification
(MLPA) as MLPA kits were available for both genes (SALSA MLPA
probemix P138 SLC2A1-STXBP1 and P015-F1MECP2). For MLPA
data analysis, we used the Coffalyser.Net tool (MRC-Holland).
95-Genes Panel Target Resequencing Analysis
The Haloplex panel was designed using the Agilent SureDesign
tool (https://earray.chem.agilent.com/suredesign/index.htm) to
capture the 95 epilepsy genes. gDNA was purified and resuspended
in water using the DNA Clean & Concentrator-5 columns (Zymo
Research Corporation, Irvine, CA) and the libraries prepared us-
ing the Haloplex target enrichment system (Agilent Technologies,
SantaClara,CA) according to themanufacturer instructions. Probes
were generated to cover all coding exons and their flanking intronic
sequences (10 base pairs padding). In brief, 225 ng of genomic
DNA was used for restriction reactions, and hybridization with the
Haloplex probe was performed for 3 hr at 54°C. Twelve libraries
containing unique identifiers were quality controlled using a 2100
Bioanalyzer (Agilent Technologies), pooled in equimolar concen-
tration and sequenced on aMiSeq sequencer using aMiSeq Reagent
Kit v3 and a 150 bp paired-end chemistry (Illumina, San Diego,
CA). Sequence reads were aligned to the NCBI37/hg19 reference
genome using a pipeline based on BWA [Li and Durbin, 2009]
and Picard (https://broadinstitute.github.io/picard/). Variants were
called using the GATK toolkit [McKenna et al., 2010].
Variants Annotation and Filtering
For both panels, variants were annotated with gene name
and classified according to their position and effect (frameshift,
truncating, splicing, coding non synonymous, coding synony-
mous, intronic) using the ANNOVAR tool [Yang and Wang,
2015]. Variants localized in intronic regions outside the 10 bp
exon flanking boundaries and in the 5’- and 3’-UTR regions
were excluded. Variants reported in the Exome Aggregation Con-
sortium (ExAC) database (http://exac.broadinstitute.org/) and/or
in the 1000 Genomes Project (http://www.1000genomes.org)
and/or in the NHLBI Exome Sequencing Project (ESP, ESP6500
database, http://evs.gs.washington.edu/EVS), with a Minor Al-
lele Frequency > 0.01 (1%) were dropped out. In silico pre-
diction of mutations’ pathogenicity were obtained using AN-
NOVAR and the dbNSFP database (v3.0a), which provides
functional prediction scores on more than 20 different algorithms
(https://sites.google.com/site/jpopgen/dbNSFP). To assess the ef-
fects of missense substitutions, we used both the dbNSFP ensemble
rank scores MetaSVM and MetaLR (Liu et al., 2016).
The cDNA numbering uses +1 as the A of the ATG translation
initiation codon in the reference sequence, with the initiation codon
as codon 1.
Variants Confirmation
Putative causative variants were analyzed by Sanger sequencing to
confirm the NGS results and investigated in the parents of probands
to check their inheritance status. The exons covering the coding
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Figure 1. A: Graphic representation of the age at seizure onset of the 71 patients carrying pathogenic mutations: 47 patients (66%) had their
first seizure prior to 6 months of age; seven patients (10%) had their first seizure between 7 and 12 months of age; 17 patients (24%) had their first
seizure between 1 and 5 years of age. B: Graphic representation of the number of patients (y-axis) carrying mutations in 30 epilepsy genes (x-axis).
regions flanking the variants were amplified by PCR. PCR products
were cycle sequenced on both strands using the BigDye Terminator
v 3.1 chemistry (Applied Biosystems, Foster City, CA) and run on a
3130XL genetic analyzer (Applied Biosystems).
Criteria for Pathogenicity of Rare or Novel Variants
We classified rare or novel variants as being “pathogenic,” “likely
pathogenic,” “variant of uncertain significance (VOUS),” “likely
benign” or “benign,” according to the international guidelines of the
ACMG Laboratory Practice Committee Working Group [Richards
et al., 2015].
We confirmed relatedness within families using the Powerplex
Fusion Kit (Promega) when de novo mutations occurred.
Results
The study included 349 patients analyzed with NGS panels. We
obtained detailed clinical information on age at seizures onset and
epilepsy/syndrome type in 300out of the 349probands (86%)whose
median age at seizure onset was 6 months (from 1st day of life to 12
years; mean 18.5 months). Probands were classified as having severe
pediatric epilepsies with variable phenotypes, including well estab-
lished syndromes such as West (57 probands), myoclonic-astatic
epilepsy (MAE) (10 probands), Landau-Kleffner (eight probands),
Ohtahara (seven probands), Dravet (DS) (six probands), electri-
cal status epilepticus in sleep (four probands), Lennox-Gastaut
(three probands), malignant migrating partial seizures of infancy
(MMPSI) (twoprobands),Angelman (twoprobands), andRett (two
probands). The remaining patients presented less-defined pheno-
types broadly classified, according to seizure type and onset, as:
neonatal EE (37 probands), early infantile EE (44 probands), late
infantile EE (20 probands), childhood EE (13 probands), neonatal
or infantile or childhooddrug-resistant focal ormultifocal epilepsies
(two, 15, and 31 probands), drug-resistant myoclonic absences (six
probands), drug-resistant absence epilepsy (five probands), gener-
alized epilepsies with febrile, and afebrile seizures (26 probands).
There were 49 patients with a diagnosis of refractory pediatric
epilepsy referred for “epilepsy genes panel screening” for whom
information on age at seizures onset and epilepsy/syndrome type
could not be retrieved. Supplementary table (Supp. Table S4) sum-
marizes ages at seizureonset (median,mean, and range) andepilepsy
type/syndromeof the 300 patients (GroupA= 30-gene panel; Group
B = 95-gene panel or both—in brackets). The only differences be-
tween the two groups were a wider age range at epilepsy onset and
a slight predominance of neonatal and early infantile EE in Group
A and of MAE and genetic generalized epilepsy in Group B.
The 349 patients were analyzed with NGS panels of 30 genes, 95
genes, or both. Eighty-six patients (24.6%) harbored novel or rare
variants, 71 (20.3%) of these variants were classified as “pathogenic”
or “likely pathogenic” mutations, whereas 15 (4.3%) were classified
as VOUS. Forty-two mutations were novel.
Using the 30-genes panel in Cohort A (207 patients), we ob-
tained a mean coverage of 95% bases covered at 10× and we
found 40 patients (40/207: 19.3%) to carry novel or rare variants
classified as “pathogenic” or “likely pathogenic”. Using the 95-genes
panel for the analysis of Cohort B (142 patients), we obtained a
mean coverage of 98% bases covered at 30× and we found 26
patients (26/142: 18.3%) to carry novel or rare variants classified as
“pathogenic” or “likely pathogenic”. Thirty-four patients, who were
mutation-negative after the 30-genes panel screening, were subse-
quently analyzed with the 95-genes panel. This analysis identified
five de novomutations (5/34: 14.7%), four of which involving genes
not included in the 30-genes panel. The c.3690dupT [p. (Ser1231∗)]
SCN1Amutationwas not identifiedwith the 30-genes panel as it had
been missed by the GSMapper toolkit, used for data analysis. Thus,
of the 176 patients analyzed with the 95-genes panel, 31 (31/176:
17.6%) carried pathogenic mutations.
Sub-analysis according to age at seizure onset of the 71 patients
carrying pathogenic mutations showed that in 66% (47/71) seizures
had started before the 6th month of life (Fig. 1A).
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Thirty epilepsy genes were found to carrymutations at least once,
ranging from nine mutations occurring in a single gene to single
mutations in 17 different genes (Fig. 1B). Most mutations involved
genes that are frequently associated with drug-resistant epilepsies
including SCN2A, SCN1A, STXBP1, KCNQ2, SCN8A, CDKL5, and
MECP2 (Fig. 1B).
SCN2A:We foundninedenovo variants involving this gene (Supp.
Table S5). Eight patients had neonatal onset EE with seizures be-
ginning within the 1st week of life, including two patients with
Ohtahara syndrome and one withMMPSI. A remaining patient had
a childhoodonset EEwithmultifocal seizures and spasmspresenting
at 17 months.
SCN1A: We found eight variants involving this gene, six of which
occurring de novo (Supp. Table S6). Although the variant c.568T>C
[p.(Trp190Arg)] could not be tested in the proband’s parents, it had
already been published as disease causing [Fukuma et al., 2004]. Six
patients had a phenotype consistent withDS, whereas the remaining
two had drug-resistant infantile onset epilepsy whose clinical and
EEG features were not reminiscent of a clearly defined syndrome.
KCNQ2: We found six de novo variants in this gene (Supp. Table
S7). Four patients exhibited a neonatal onset EE, including one with
Ohtahara syndrome. The remaining two probands manifested an
early infantile epileptic encephalopathy (EIEE) with drug-resistant
polymorphic seizures appearing 9 and 16 days after birth.
STXBP1:We found six de novo variants involving this gene (Supp.
Table S8). Four patients exhibited a neonatal onset EE including
one with Ohtahara syndrome, whereas the remaining two patients
exhibited an EIEE with seizures occurring at 4 months and the last
patient manifested a drug-resistant epilepsy with multifocal seizure
at 12 months. Among the STXBP1 variants, we identified a de novo
intragenic duplication of 17.5 kb, spanning from exon 4 to exon 15
(Supp. Fig. S1). This is the first large duplication reported to involve
STXBP1. The patient’s phenotype was similar to that described with
partial deletions of the same gene [Saitsu et al., 2008, Milh et al.,
2011]. In silico prediction analysis revealed the in-frame duplication
not to cause a premature truncation of the protein, despite the
introduction of 371 additional aminoacids. However, we cannot
exclude that the rearrangementmight lead tomRNAdestabilization
with consequent absence of protein product or to a misfolding of
the mutant protein.
SCN8A: We found five variants involving this gene, four
of which occurring de novo (Supp. Table S9). The c.5630A>G
[p.(Asn1877Ser)] variant (reported as disease causing by Anand
et al., 2016)was inherited froman affectedmotherwhose phenotype
was comparable to that of her daughter. The phenotype associated
with the inherited mutation observed in both the proband and her
mother wasmild withmoderate cognitive impairment and infantile
onset focal seizures persisting throughout life with a monthly fre-
quency. Four patients exhibited an EIEEwith seizures onset between
3 and 4 months.
CDKL5: We found four de novo variants, in two girls and two
boys, involving this gene (Supp. Table S10). The c.1247 1248del
[p.(Glu416Valfs∗2)] (already reported as disease causing by Ray-
mond et al., 2013) was a mosaic mutation occurring in a hemizy-
gous boy. Patients had an EIEEwith amean age at onset of 2months
(ranging from 1 to 3 months), the phenotype was very severe in-
cluding West syndrome in two2 patients.
MECP2: We found four de novo variants in this gene (Supp. Table
S11), all exhibiting aphenotype consistentwithRett syndrome, asso-
ciatedwith drug-resistant epilepsy, with seizures onset ranging from
22 months to 5 years (onset at a mean age of 3 years). The patient
carrying the c.915G>T [p.(Lys305Asn)] missense mutation exhib-
ited drug-resistant focal, nocturnal seizures in childhood. During
adolescence the clinical picture progressed to a phenotype resem-
bling the PPM-X: intellectual disability with parkinsonism, pyra-
midal signs, and neuropsychiatric symptoms, described in males
[Lindsay et al., 1996]. Among the MECP2 variants, we identified a
de novo intragenic deletion of 4.1 kb, involving the whole exon 3
and part of exon 4 (Supp. Fig. S1).
Rare Mutations
KCNT1,UBE3A, SPTAN1, SYNGAP1,HCN1, andGABRB3 genes
were found to carry mutations in two patients each (Supp. Table
S12).All variantsweredemonstrated tobedenovowith the exception
of the c.1546A>G [p.(Met516Val)] variant in the KCNT1 gene for
which parental DNA was not available for testing. We classified this
variant as “likely pathogenic” since it was previously reported to be
disease causing by Rizzo et al. (2016).
The phenotypes of patients carrying mutations in these genes
were typical, including MMPSI associated with KCNT1 mutations
[Barcia et al., 2012] andAngelman syndromeassociatedwithUBE3A
mutations [Sadikovic et al., 2014]. Of the two probands with SP-
TAN1 mutations, one had a severe EIEE with suppression-burst
EEG pattern and MRI findings of pontocerebellar and corpus cal-
losum atrophy; the other patient manifested a less severe pheno-
type with drug-resistant focal epilepsy, mild cognitive impairment
and Attention-Deficit/Hyperactivity Disorder. Both phenotypes re-
semble those already described in the literature [Tohyama et al.,
2015]. Likewise, the two probands with SYNGAP1 mutations ex-
hibited different clinical disorders, one patient manifested early and
progressive developmental delay with prominent autistic features
with self-directed aggressive behavior and childhood-onset drug-
resistant generalized epilepsy [Mignot et al., 2016], whereas the
second patient had West syndrome since the 4th month of life. Two
patients carried HCN1 mutations, associated, in one, to a DS-like
phenotype consisting of febrile and afebrile seizures since the age
of 5 months, as previously described [Nava et al., 2014], whereas
the second patient exhibited a catastrophic neonatal onset EE with
almost continuous multifocal seizures, with prominent autonomic
semiology, including prolonged apnea and severe cyanosis. He died
at 14 months due to cardiopulmonary failure. The last two patients
harboredGABRB3mutations and exhibited EIEEwith polymorphic
drug-resistant seizures and West syndrome.
Single variants were identified in KCNB1, IQSEQ2, GABRG2,
GABRA1, ARX, PCDH19, SLC25A22, MEF2C, CNTNAP2, PNPO,
DEPDC5, PDHA1, PIGA, GNAO1, KCNA1, ATP1A2, and KCNA2.
The segregation of variants identified in the PCDH19, GABRG2,
and SLC25A22 genes could not be performed since parental DNA
was not available. However, these variants were classified as “likely
pathogenic” since the patients’ phenotype was consistent with pre-
vious descriptions of patients carrying mutations in each of these
genes. The clinical features of patients carrying mutations in these
17 genes are summarized in Table 1.
Fifteen variants (15 out of 349: 4.3%) were classified as VOUS
[Richards et al., 2015] (Supp. Table S13).
Discussion
Targeted resequencing in 349 patients with pediatric drug-
resistant epilepsies analyzed with two epilepsy gene panels detected
71 pathogenic mutations, 42 of which novel, in 30 different genes
in 20.3% of probands. This diagnostic yield compares to previous
NGS studies in epilepsy, in which rates of disease-causing variants
range from 10% to 22.6% [Carvill et al., 2013; Kodera et al., 2013;
HUMANMUTATION, Vol. 38, No. 2, 216–225, 2017 219
Ta
bl
e
1.
G
en
es
w
ith
M
ut
at
io
ns
in
O
ne
Pa
tie
nt
Ea
ch
Pa
ti
en
t
G
en
de
r
A
ge
P
h
en
ot
yp
e
A
ge
at
Se
iz
u
re
O
n
se
t
N
G
S
Pa
n
el
G
en
e
M
u
ta
ti
on
Ty
p
e
In
h
er
it
an
ce
R
ef
er
en
ce
E
xA
C
D
at
ab
as
e
V
er
si
on
0.
3.
1
A
lt
er
n
at
e
A
lle
le
C
ou
n
t
/T
ot
al
A
lle
le
N
u
m
be
r;
A
lle
le
Fr
eq
u
en
cy
)
M
et
a
SV
M
/
M
et
aL
R
(L
iu
et
al
.,
20
16
)
A
C
M
G
C
ri
te
ri
a
(R
ic
h
ar
ds
et
al
.,
20
15
)
A
C
M
G
C
la
ss
ifi
-
ca
ti
on
35
3R
F
6
ye
ar
s
N
O
E
E
18
da
ys
95
ge
n
es
K
C
N
A
1
N
M
00
02
17
.2
:c
.1
21
4C
>
T
p.
(P
ro
40
5L
eu
)
M
is
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
2,
P
P
2,
P
P
3
LP
20
65
P
F
4
ye
ar
s
D
ru
g-
re
si
st
an
t
ep
ile
ps
y
w
it
h
fe
br
ile
an
d
af
eb
ri
le
se
iz
u
re
s
16
m
on
th
s
95
ge
n
es
K
C
N
A
2
N
M
00
49
74
.3
:c
.9
71
G
>
C
p.
(S
er
32
4T
h
r)
M
is
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
2,
P
P
2,
P
P
3
LP
15
39
P
M
6
ye
ar
s
W
es
t
sy
n
dr
om
e,
au
ti
sm
sp
ec
tr
u
m
di
so
rd
er
9
m
on
th
s
95
ge
n
es
K
C
N
B
1
N
M
00
49
75
.2
:c
.1
10
9G
>
A
p.
(T
rp
37
0X
)
N
on
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
N
A
P
V
S1
,P
S2
,P
M
2
P
38
4N
M
7
ye
ar
s
IO
E
E
7
m
on
th
s
95
ge
n
es
G
A
B
R
A
1
N
M
00
08
06
.5
:c
.4
36
C
>
A
p.
(L
eu
14
6M
et
)
M
is
se
n
se
D
e
no
vo
Jo
h
an
n
es
en
et
al
.,
20
16
∗
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
2,
P
P
2,
P
P
3
LP
59
1P
N
6
ye
ar
s
G
en
er
al
iz
ed
ep
ile
ps
y
w
it
h
m
yo
cl
on
ic
at
on
ic
-s
ei
zu
re
s,
co
gn
it
iv
e
im
pa
ir
m
en
t,
be
h
av
io
ra
ld
is
or
de
r
3
ye
ar
s
95
ge
n
es
G
A
B
R
G
2
N
M
00
08
16
.3
:c
.8
21
A
>
G
p.
(T
yr
27
4C
ys
)
M
is
se
n
se
Pa
re
n
ts
n
ot
av
ai
la
bl
e
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
M
2,
P
M
6,
P
P
2,
P
P
3
LP
10
98
M
F
6
ye
ar
s
C
h
ild
h
oo
d
E
E
w
it
h
au
ti
sm
sp
ec
tr
u
m
di
so
rd
er
,m
ic
ro
ce
ph
al
y
19
m
on
th
s
95
ge
n
es
IQ
SE
C
2
N
M
00
11
11
12
5.
2:
c.
40
39
du
pG
p.
(A
la
13
47
G
ly
fs
∗4
0)
Fr
am
es
h
if
t
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
N
A
P
V
S1
,P
S2
,P
M
2
P
12
21
P
F
18
ye
ar
s
D
ru
g-
re
si
st
an
t
fo
ca
l
ep
ile
ps
y
w
it
h
cl
u
st
er
s
of
fo
ca
lf
eb
ri
le
an
d
af
eb
ri
le
se
iz
u
re
s
2
ye
ar
s
95
ge
n
es
P
C
D
H
19
N
M
00
11
84
88
0.
1:
c.
13
39
A
>
C
p.
(A
sn
44
7H
is
)
M
is
se
n
se
Pa
re
n
ts
n
ot
av
ai
la
bl
e
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
M
2,
P
M
6,
P
P
2,
P
P
3
LP
17
4R
M
2
ye
ar
s
O
h
ta
h
ar
a
sy
n
dr
om
e
1
m
on
th
30
ge
n
es
SL
C
25
A
22
N
M
02
46
98
.5
:c
.3
94
C
>
T
p.
(G
ln
13
2X
)
N
on
se
n
se
Pa
re
n
ts
n
ot
av
ai
la
bl
e
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
N
A
P
V
S1
,P
M
2
LP
29
5M
M
8
ye
ar
s
IO
E
E
w
it
h
au
ti
sm
sp
ec
tr
u
m
di
so
rd
er
12
m
on
th
s
30
ge
n
es
M
E
F2
C
N
M
00
23
97
.4
:c
.1
08
C
>
A
p.
(S
er
36
A
rg
)
M
is
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
2,
P
P
2
LP
78
1M
M
6
ye
ar
s
D
ru
g-
re
si
st
an
t
fo
ca
l
ep
ile
ps
y,
se
ve
re
co
gn
it
iv
e
im
pa
ir
m
en
t
16
m
on
th
s
30
ge
n
es
C
N
T
N
A
P
2
N
M
01
41
41
.5
:c
.1
77
7+
2T
>
C
Sp
lic
e
si
te
H
om
oz
yg
ou
s
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
N
A
P
V
S1
,P
M
2,
P
M
3
P
54
3N
M
4
ye
ar
s
IO
E
E
,c
or
pu
s
ca
llo
su
m
hy
po
pl
as
ia
,s
im
pl
ifi
ed
gy
ra
lp
at
te
rn
4
m
on
th
s
30
ge
n
es
A
R
X
N
M
13
90
58
.2
:c
.1
05
8C
>
T
p.
(P
ro
35
3L
eu
)
M
is
se
n
se
D
e
no
vo
St
ro
m
m
e
et
al
.,
20
02
N
ot
pr
es
en
t
D
/D
P
S1
,P
S2
,P
M
2,
P
M
5,
P
P
2,
P
P
3
P
27
8N
M
9
ye
ar
s
N
O
E
E
1
da
y
30
ge
n
es
P
N
P
O
N
M
01
81
29
.3
:c
.6
74
G
>
A
p.
(A
rg
22
5H
is
)
M
is
se
n
se
H
om
oz
yg
ou
s
P
le
ck
o
et
al
.,
20
14
7/
12
13
98
;
0.
00
00
57
66
D
/D
P
S1
,P
S3
,P
M
2,
P
M
3,
P
P
2,
P
P
3
P
26
1H
F
20
ye
ar
s
D
ru
g-
re
si
st
an
t
fo
ca
l
ep
ile
ps
y
2
ye
ar
s
95
ge
n
es
D
E
P
D
C
5
N
M
00
12
42
89
6.
1:
c.
32
30
32
34
de
l
p.
(A
la
10
77
A
sp
fs
∗8
2)
Fr
am
es
h
if
t
M
at
er
n
al
ly
in
h
er
it
ed
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
N
A
P
V
S1
,P
M
2,
P
M
4,
P
P
1,
P
P
4
P
14
14
P
F
6
ye
ar
s
IO
E
E
,m
ic
ro
ce
ph
al
y,
br
ai
n
at
ro
ph
y,
pa
rt
ia
l
co
rp
u
s
ca
llo
su
m
ag
en
es
is
9
m
on
th
s
95
ge
n
es
P
D
H
A
1
N
M
00
02
84
.3
:c
.9
04
C
>
T
p.
(A
rg
30
2C
ys
)
M
is
se
n
se
D
e
no
vo
D
ah
le
t
al
.,
19
92
N
ot
pr
es
en
t
D
/D
P
S1
,P
S2
,P
S3
,P
M
1,
P
M
2,
P
M
5,
P
P
3
P
(C
on
ti
nu
ed
)
220 HUMANMUTATION, Vol. 38, No. 2, 216–225, 2017
Ta
bl
e
1.
Co
nt
in
ue
d
Pa
ti
en
t
G
en
de
r
A
ge
P
h
en
ot
yp
e
A
ge
at
Se
iz
u
re
O
n
se
t
N
G
S
Pa
n
el
G
en
e
M
u
ta
ti
on
Ty
p
e
In
h
er
it
an
ce
R
ef
er
en
ce
E
xA
C
D
at
ab
as
e
V
er
si
on
0.
3.
1
A
lt
er
n
at
e
A
lle
le
C
ou
n
t
/T
ot
al
A
lle
le
N
u
m
be
r;
A
lle
le
Fr
eq
u
en
cy
)
M
et
a
SV
M
/
M
et
aL
R
(L
iu
et
al
.,
20
16
)
A
C
M
G
C
ri
te
ri
a
(R
ic
h
ar
ds
et
al
.,
20
15
)
A
C
M
G
C
la
ss
ifi
-
ca
ti
on
16
39
R
M
2
ye
ar
s
IO
E
E
,m
ov
em
en
t
di
so
rd
er
w
it
h
dy
sk
in
es
ia
s,
m
ic
ro
ce
ph
al
y
6
m
on
th
s
95
ge
n
es
P
IG
A
N
M
00
26
41
.3
:c
.4
04
C
>
T
p.
(A
la
13
5V
al
)
M
is
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
T
/T
P
S2
,P
M
2,
B
P
4
LP
28
1P
M
6
ye
ar
s
D
ru
g-
re
si
st
an
t
fo
ca
l
ep
ile
ps
y,
se
ve
re
co
gn
it
iv
e
im
pa
ir
m
en
t,
m
ov
em
en
t
di
so
rd
er
w
it
h
dy
sk
in
es
ia
s,
m
ic
ro
ce
ph
al
y
8
m
on
th
s
95
ge
n
es
G
N
A
O
1
N
M
02
09
88
.2
:c
.6
25
C
>
T
p.
(A
rg
20
9C
ys
)
M
is
se
n
se
D
e
no
vo
Sa
it
su
et
al
.,
20
16
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
1,
P
M
2,
P
P
2,
P
P
3
P
41
3N
M
4
ye
ar
s
E
IE
E
1
m
on
th
30
ge
n
es
AT
P
1A
2
N
M
00
07
02
.3
:c
.1
09
7G
>
C
p.
(G
ly
36
6A
la
)
M
is
se
n
se
D
e
no
vo
N
ot
re
po
rt
ed
N
ot
pr
es
en
t
D
/D
P
S2
,P
M
2,
P
P
2,
P
P
3
LP
M
,m
al
e;
F,
fe
m
al
e;
E
E
,e
pi
le
pt
ic
en
ce
ph
al
op
at
hy
;N
O
E
E
,N
eo
n
at
al
O
n
se
t
E
pi
le
pt
ic
E
n
ce
ph
al
op
at
hy
;I
O
E
E
,I
n
fa
n
ti
le
O
n
se
t
E
pi
le
pt
ic
E
n
ce
ph
al
op
at
hy
;D
,D
el
et
er
io
u
s;
T,
To
le
ra
te
d;
P,
Pa
th
og
en
ic
;L
P,
Li
ke
ly
pa
th
og
en
ic
;N
A
,N
ot
ap
pl
ic
ab
le
;
∗,
sa
m
e
pa
ti
en
t.
Wang et al., 2014; Mercimek-Mahmutoglu et al., 2015; Trump et al.,
2016]. Patients selection for gene panel analysis might influence the
mutation rate. The proportion ofmutations identified in our cohort
might be slightly underestimated especially for the SCN1A, SLC2A1,
and PCDH19 genes since their pathogenic variants are usually as-
sociated to relatively specific phenotypes, often prompting direct
sequencing as single genes. Indeed, in the same time frame of our
study (2013–2015), guided by clinical features directing to distinc-
tive phenotypes, through Sanger sequencing, we identified SCN1A
mutations in 73 patients, SLC2A1 mutations in 16 and PCDH19
mutations in 13. There is one NGS study with a diagnostic yield
reaching nearly 50% in which, however, the analysis was performed
in a small cohort of patients [Lemke et al., 2012]. This proportion
has remained much higher than subsequently reported, likely due
to both the large number of targeted genes (265) and selection bias
toward probands with distinctive phenotypes, such as for example
DS, ceroid lipofuscinosis, and periventricular nodular heterotopia
[Lemke et al., 2012].
At first sight, the sub-analysis and comparison of the two NGS
panels used in this study (30 vs. 95 genes) indicates similarmutation-
detection rates. Re-analysis of a small cohort of probands who were
mutation-negative after the 30-genes panel screening, uncovered
“pathogenic” mutations only in five additional patients, one of
which involving a gene already included in the first panel. How-
ever, if all 349 patients had been analyzed with the 30-genes panel,
we would have obtained only 49 mutations corresponding to 14.0%
(49/349) diagnostic yield. Otherwise, if only the 95-genes panel
were used, it would have identified all 71 mutations, leading to a
detection-rate equal to, or likely higher than, 20.3% (71/349). Thus,
the expansion of the panel from 30 to 95 genes brought to an in-
crease of about 25% in the diagnostic yield, providing a diagnosis
that would have otherwise been missed in 22 additional patients
(22/349: 6.3%).
Clinical evaluationof patients carrying pathogenic variants shows
that 66% of them had their first seizure prior to 6 months of age
(Fig. 1A). This finding confirms that current NGS analysis leads to
the highest diagnostic yield in patients with early infantile onset
epilepsies [Trump et al., 2016].
Among the71disease-causing variants, 42 (59.2%) involvedgenes
that are usually associated to EIEE (Supp. Tables S5–S11) includ-
ing SCN2A (nine mutations, 12.9%) with the higher number of
pathogenic variants followed by SCN1A (eight mutations, 11.4%),
KCNQ2 and STXBP1 (six mutations, 8.6%), SCN8A (five muta-
tions, 7.1%), CDKL5 andMECP2 (four mutations, 5.7%) (Fig. 1B).
Besides SCN1A, for which the rate of mutation positive patients
is undersized in our series, due to this gene being often individu-
ally screened, for the remaining genes, our findings show that in
a heterogeneous cohort of pediatric drug-resistant epilepsies the
possibility of harboring mutations in other genes reaches 2.6% for
SCN2A, 1.7% for both KCNQ2 and STXBP1, 1.4% for SCN8A, and
1.1% for CDKL5 or MECP2. NGS of cohorts of patients with an
age at seizure onset of less than 6 months might lead to higher
percentages for each of these genes.
Although SCN8A mutations associated with severe EIEE are de
novo [Larsen et al., 2015] recently, a few familial cases carrying
dominant mutations have been reported in association with benign
familial infantile seizures and paroxysmal dyskinesia [Gardella et al.,
2016]. In our cohort, one of the five SCN8Amutations had familial
distribution, segregating in the proband and in her affected mother,
both exhibiting moderate cognitive impairment and infantile onset
focal seizures persisting throughout life with a monthly frequency.
The samemutationhasbeen reported in a small familywith earlyon-
set focal seizures and no cognitive impairment [Anand et al., 2016].
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Twenty-nine disease-causing mutations (40.8%) were identified
in 23 additional genes (Table 1, Supp. Table S12, and Fig. 1B), most
of them recently associated with epilepsy and thus with phenotypes
not fully characterized.
A subset of patients included in our cohort (Supp. Table S3)
had undergone individual genes screening prior to being analyzed
using one or both gene panels and two pathogenic variants, one
in SCN1A and one in UBE3A, identified using the panels were
undetected by Sanger sequencing, confirming that NGS has the
potential of detecting previously missed mutation negative DS and
Angelman syndrome patients. For example, Dje´mie´ et al. (2016)
reported SCN1Amutations identified with NGS but initially missed
using Sanger sequencing.
An added value of medium size NGS panels, including the one
used in our laboratory targeting 95 epilepsy genes, is the detection of
mutations in genes accounting for rare disorders that are usually not
studied in diagnostic settings. Detection of novel mutation-positive
patients allows broadening the clinical phenotype and better delin-
eating the electroclinical features of seizures related tomutations in a
given gene. For instance, mutations in theHCN1 gene were recently
associated to a phenotype resembling DS in six probands [Nava
et al., 2014]. We identified two HCN1 novel missense mutations
confirming the DS like phenotype in one proband but expanding
the phenotype to a catastrophic neonatal onset EE with almost con-
tinuous multifocal seizures leading to early death in one child. Like-
wise, mutations in SYNGAP1 were reported in patients with early
onset developmental delay followed by autistic features and child-
hood onset refractory generalized epilepsy with atypical absences
or myoclonic-atonic seizures [Mignot et al., 2016]. We identified
twomutations in this gene associated with a phenotype overlapping
previous descriptions in one patient, whereas the other patient ex-
hibited West syndrome. Therefore, SYNGAP1 can be added to the
list of genes that might cause infantile spasms. A single mutation
was identified in the ATP1A2 gene in a child with severe EE with
seizures onset in the 1st month of life. Mutations in this gene are
usually associated with familial hemiplegic migraine that rarely co-
occurs with seizures [Bianchin et al., 2010]. ATP1A2, together with
ATP1A3, belongs to a family of genes coding for catalytic subunits
of Na/K-ATPase. The relevance of these genes in genetic epilepsies
is also supported by the report of a child with catastrophic early
life epilepsy and shortened survival carrying a mutation in ATP1A3
[Paciorkowski et al., 2015].
Singlemutationswere identified inGNAO1 andPIGA genes, both
associated to EIEE including Ohtahara syndrome and migrating
partial seizures [Nakamura et al., 2013, Kato et al., 2014; Saitsu et al.,
2016]; mutations of GNAO1 also cause a severe movement disorder
[Ananth et al., 2016; Saitsu et al., 2016]. Our findings confirm the
association of severe early onset epilepsy andmovement disorder in
the proband with the GNAO1 pathogenic variant, yet a prominent
dystonic/dyskinetic movement disorder was also observed in the
proband carrying PIGAmutation.
Genes related to sodium channel function including SCN1A,
SCN2A,SCN8A,SCN9A, andSCN1Bhave longbeenknown tobe as-
sociated with epilepsy of variable severity [Hildebrand et al., 2013;
Brunklaus et al., 2014]. In our patients, sodium channelopathies
accounted for 6.3% of the total cohort (22/349) and for about
one-third of mutated genes (22/70: 31.4%). Likewise, potassium
channelopathies are emerging as a major cause of EE and the list
of voltage-gated potassium channel genes associated with epilepsy
is growing to include KCNB1 [Torkamani et al., 2014; Saitsu et al.,
2015; Allen et al., 2016], KCNA1 [Eunson et al., 2000] and KCNA2
[Syrbe et al., 2015], in addition to the initial reports on KCNT1
[Barcia et al., 2012] and KCNQ2 [Weckhuysen et al., 2012; Kato
et al., 2013]. In our series, potassium channelopathies accounted for
3.1% of the total cohort (11/349) and about 15% of mutated genes
(11/70: 15.7%). Among them, using the 95-genes panel, we uncov-
ered mutations in these genes in three patients whose phenotype
was concordant with previously published probands for KCNQ2
and KCNT1, whereas the child harboring the KCNB1mutation ex-
hibited West syndrome. There are only seven patients reported to
carry missense mutations in this gene and three of them presented
infantile spasms [Torkamani et al., 2014, Saitsu et al., 2015; Allen
et al., 2016]. The patient carrying the KCNA2 variant exhibited
late infantile drug-resistant seizures followed by a good outcome
with seizure-freedom in childhood, confirming the spectrum of
KCNA2-related phenotypes from early and severe infantile EE to
mild epilepsy with good outcome [Syrbe et al., 2015]. The severity
of the phenotypes appears to correlate with the genotype: gain-
of-function mutations are more severe with persistent seizures. In
contrast, patients with loss-of-functionmutations have later seizure
onset, and achieve seizure freedom in childhood [Syrbe et al., 2015].
We hypothesize that our patient belongs to this latter group. Our
95-genes panel included the KCNA1 gene, which has previously
been associated to episodic ataxia/myokymia syndrome in humans
[Browne et al., 1994] and to limbic seizure-phenotype similar to
temporal lobe epilepsy in Kcna1-null mice [Robbins et al., 2012].
We identified a de novo KCNA1 variant in a patient with refrac-
tory neonatal onset focal seizures whose semiology, as the child
grew older, progressed to facial fearful expression with automatisms
mimicking hold and reassurance seeking. Such semiology is sug-
gestive of a limbic origin of seizures, as also observed in the mouse
model. Thus, the gene function, de novo occurrence, and the simi-
larity with the mouse model support a causative role for theKCNA1
variant.
Array-CGH was only prformed in one third of our patients
since the diagnostic yield of this approach is considered to be
low in patients with a pure EE phenotype (about 3%) [Epilepsy
Phenome/Genome Project Epi4K Consortium, 2016]. Array-CGH
reaches instead higher percentages of positive findings when
epilepsies co-occur with additional findings such as abnormal MRI,
developmental delay, or dysmorphic features [Mefford, 2015]. Yet,
patients with drug-resistant epilepsy and no additional features
are more likely to carry intragenic rearrangements that might be
uncovered by methods including exon-level microarray, which
represent a useful complement to gene panel analysis. Indeed,
using the GS Mapper tool and the long reads generated by the
454 pyrosequencing of the 30-genes panel, we identified one large
duplication in STXBP1 and one large deletion inMECP2.
NGSpanels, nowusedwidely in clinical settings to identify genetic
causes of epilepsy, have greatly improved and expedited the diagnos-
tic approach to patients with intractable epilepsy. The results of such
panels help the diagnostic process and solve complex and puzzling
cases. They also help clinicians improving management, avoiding
numerous investigations including invasive procedures, prognos-
tication, guiding treatment choices in some cases, and providing
appropriate genetic counseling to families.
Considering the rapid advances in the area of epilepsy genetics, a
gene panel might soon become obsolete. In both our panels, genes
that were considered pathogenic at the time of the panel design and
now reclassified as susceptibility loci (i.e.,CLCN2, EFHC1) or as loci
of conflicting interpretation (i.e., PRICKLE2) should be removed.
However, genes that were not recognized as disease causing at the
time of the panel design (i.e., ALG13, SLC1A2) were not included.
For this reason, a continuous revision of a gene panel is advised,
through redesign and revalidation before its implementation in the
molecular diagnosis process. An updated version of the currently
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gene panel used in our Neurogenetics Laboratory has been included
in the supplementary material (Supp. Table 14S).
In conclusion, larger and more comprehensive panels may be in-
dicated when the phenotype is not specific of well-defined epilepsy
syndromes, as they enable molecular diagnosis of atypical pheno-
types, thus allowing to broaden phenotype–genotype correlations.
In the diagnostic setting, carefully and frequently updated gene
panels targeting about 100 epilepsy genes allow a good sequence
coverage of each gene, requiring manageable bioinformatic analy-
sis, with affordable costs. These panels have become cheaper while
turnaround time for results is also decreasing. The cost of a gene
panel analysis in a diagnostic setting is now similar to that of Sanger
sequencing for a single gene. Therefore, while targeted single-gene
Sanger sequencingmay remain appropriate in some cases, for exam-
ple, typical SCN1A-related phenotypes or classical Rett syndrome
(MECP2) or GLUT1 deficiency syndrome with hypoglycorrhachia,
our data strongly support the use of panel-based analysis as the
diagnostic genetic test of choice in the majority of individuals with
intractable early-onset seizure.
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